Tislelizumab Combined With Recombinant Human Endostatin Injection Plus Chemotherapy in Unresectable Stage III NSCLC: a Prospective, Single-arm, Multicenter Phase II Clinical Study
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Tislelizumab (Primary) ; Endostatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Oct 2024 New trial record